What is GLP-2 T? GIP/GLP-1 Dual Agonist Research Guide

Tirzepatide is a dual-agonist peptide engaging the GLP-1 and GIP receptors. In this catalogue it is listed under the coded designation GLP2 T — the two names refer to the same material, and this page states the mapping plainly so that researchers searching either one arrive in the right place.

What is tirzepatide?

A synthetic peptide designed to engage two receptors rather than one. Single-agonist peptides in this class act at the GLP-1 receptor alone; tirzepatide adds the GIP receptor. That is the structural fact the phrase “dual agonist” describes, and everything else about how it is studied follows from it.

Whether two targets is better than one is not a question a catalogue page can settle. What can be stated is the design and the trade it implies: two receptor pathways means two candidate explanations for anything measured, plus whatever their interaction contributes. That is a cost to research design, not automatically a benefit.

Why is it listed as GLP2 T?

Because listings here use coded designations for compounds in this class, and the number records how many receptors the compound engages. The convention runs GLP1 S (single), GLP2 T (dual), GLP3 R (triple). Tirzepatide, as a dual agonist, is GLP2 T.

A fuller side-by-side is on the semaglutide vs tirzepatide comparison, and the triple agonist is covered on what is retatrutide.

Is this tirzepatide peptide the same as a compounded product?

No, and the distinction is legal as well as practical. Compounding is a pharmacy activity carried out under a pharmacist’s licence to prepare a formulation to order. What is supplied here is characterised research material: lyophilised powder, per-batch certificate, for in-vitro laboratory use.

Searches for “compounded tirzepatide” or “tirzepatide compound” are usually looking for that pharmacy category. If that is what brought you here, the accurate answer is that this is a different kind of thing. Saying otherwise would be a misrepresentation, so the page says it plainly instead.

What does tirzepatide cost?

$70 per vial at current list price. Price comparison in this category only means something per milligram, and that requires knowing the fill weight — two vials at the same headline price are not comparable if one holds twice the material. The GLP2 T product page states its fill weight, and the reconstitution calculator converts weight and diluent volume into concentration and units per syringe mark.

A price far below the category average is a question rather than a bargain. These are long synthetic sequences, and length is where both cost and failure risk come from.

Buying tirzepatide online: what is actually checkable

Rather than assert that one supplier is better, here are the four things any researcher can verify before buying from anyone:

• A per-batch certificate, not a specimen. A certificate naming no batch establishes that a laboratory once tested some material, not that it tested yours.
• The analytical method named. “99.2% by RP-HPLC at 214nm” is a measurement; “>99% purity” alone is a claim.
• Mass confirmation. For a peptide this long the realistic failure is a truncated sequence — still a peptide, still passing a generic purity assay, still the wrong molecule.
• Fill quantity. Purity says how much of the vial is one substance; it says nothing about how much substance is in the vial.

Every batch sold here publishes its certificate on the test results page.

Why mass confirmation matters more than the purity headline

Purity is the number displayed most prominently on most certificates, and for a long peptide it is answering the easier question. A synthesis that terminates early produces a shorter chain that is chemically clean, chromatographically well-behaved, and not the compound on the label. A purity assay reports it as pure. A mass determination catches it.

This is why the short peptides in this catalogue carry a different risk profile from the long ones. KPV, at three residues, fails identity outright when a synthesis goes wrong — there is nowhere for a near-miss to hide. A dual agonist has room for one. The practical rule: on any long sequence, treat a certificate without a mass determination as incomplete regardless of how impressive the purity figure looks.

Reconstitution and handling

The arithmetic is total peptide mass divided by diluent volume, set by the concentration wanted rather than by the compound. A 10mg vial with 2mL gives 5mg/mL; the same vial with 1mL gives 10mg/mL. Neither is more correct, and carrying a volume across from a different fill weight without re-checking is the most common arithmetic error in this category.

Use Bacteriostatic Water where the vial will be drawn from more than once — the benzyl alcohol preservative is the entire reason to prefer it over sterile water. Bring the vial to room temperature before piercing the stopper, add diluent down the wall rather than onto the lyophilised cake, and swirl rather than shake. Full method: bacteriostatic water for research peptides.

In solution the material is markedly less stable than as dry powder, so match the reconstitution volume to how quickly the vial will actually be consumed rather than filling it because it is large.

What the second receptor actually adds

GIP is a distinct incretin receptor from GLP-1, and engaging both is the entire design premise of a dual agonist. What that produces is a matter for the primary literature rather than for a catalogue page, but the structural consequence is worth stating because it is often skipped: a compound with two receptor targets generates observations that cannot be attributed to either target on its own without further work.

For a researcher this is the practical difference between the three compounds in this family. A single agonist gives one pathway to reason about. A dual gives two plus an interaction. A triple gives three plus more interactions. Attribution gets harder in exactly that order, and no amount of repetition with the same compound resolves it — separating the contributions requires separate compounds, which is one legitimate reason to stock all three rather than only the newest.

It also explains why cross-compound comparisons in this family are more useful than they look. Running a dual agonist alongside GLP1 S / semaglutide is not redundancy; the single agonist is the control that makes the second receptor’s contribution visible at all.

Storage, vial economics, and the mistake that costs material

Lyophilised material ships dry and tolerates ambient transit, which is why it arrives without cold-chain packaging and why that is not a defect. Long-term storage is cold and dark. The step people skip is bringing the vial to room temperature before the stopper is pierced: solvent entering a cold vial invites condensation, and condensation is water arriving from somewhere other than the diluent you measured.

The second-order cost is exposure time. Reconstituted peptide is markedly less stable than dry powder, so a concentration chosen for convenience rather than for consumption rate leaves material sitting in solution for weeks longer than necessary. Sizing the reconstitution to the pace of the work is free and removes a whole class of degradation before it starts.

How does it sit against the rest of the catalogue?

Only GLP1 S and GLP3 R are in the same class. Everything else stocked here works by unrelated mechanisms: Tesa-morelin and Ipamorelin act on the pituitary, MOTS-C and SS31 – 10mg are mitochondrially associated, BPC-157 and TB-500 are fragments of larger proteins, and GHK-Cu (Copper Peptide) is a copper-coordinated tripeptide. Comparisons across those groups are category errors, however often they get made.

Frequently asked questions

Where to read the primary literature

Live searches against the two public registries, not curated citations.

• PubMed: tirzepatide · ClinicalTrials.gov: tirzepatide
• PubMed: GIP receptor agonist · ClinicalTrials.gov: dual agonist

All materials listed are supplied strictly for in-vitro laboratory and research use. They are not drugs, foods or cosmetics, are not for human or veterinary use, and nothing on this page describes an intended use in humans. Figures quoted are catalogue list prices at the time of writing.